Latest Gonadotropin-releasing hormone Stories
MORRISTOWN, N.J., March 11 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced the U.S.
Previous work in birds and sheep shows a wealth of clinical possibilities.
BETHESDA, Md., Dec. 4 /PRNewswire/ -- Drs. Neal Shore and E.
WHITEHOUSE STATION, N.J., Nov. 20 /PRNewswire-FirstCall/ -- Merck & Co., Inc.
PARSIPPANY, N.J., Aug. 4 /PRNewswire/ -- Ferring Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved the trade name FIRMAGON(R) (degarelix for injection) for its prostate cancer treatment previously marketed under the generic name degarelix.
University of California, Berkeley, researchers have found what they think is a critical and, until now, missing piece of the puzzle about how stress causes sexual dysfunction and infertility.
SAN DIEGO, June 16 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
QUEBEC CITY, June 1 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
New Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist Demonstrates Rapid, Long-term Suppression of Testosterone - a hormone that stimulates prostate cancer growth. PARSIPPANY, N.J., Dec. 24 /PRNewswire/ -- Ferring Pharmaceuticals, USA today received approval from the U.S.
SAINT PREX, Switzerland, December 18 /PRNewswire/ -- - New Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist Demonstrates Rapid, Long-Term Suppression of Testosterone Ferring Pharmaceuticals received today notification that the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency (EMEA), has adopted a positive opinion and is recommending to grant a marketing authorization for FIRMAGON(R) (degarelix), a new GnRH receptor antagonist...
- The parings of haberdine; also, any kind of fragments.